Weissinger, E M ; Metzger, J 
; Dobbelstein, C ; Wolff, D ; Schleuning, M ; Kuzmina, Z ; Greinix, H ; Dickinson, A M ; Mullen, W ; Kreipe, H ; Hamwi, I ; Morgan, M ; Krons, A ; Tchebotarenko, I ; Ihlenburg-Schwarz, D ; Dammann, E ; Collin, M ; Ehrlich, S ; Diedrich, H ; Stadler, M ; Eder, M ; Holler, E ; Mischak, H ; Krauter, J ; Ganser, A
; Dobbelstein, C ; Wolff, D ; Schleuning, M ; Kuzmina, Z ; Greinix, H ; Dickinson, A M ; Mullen, W ; Kreipe, H ; Hamwi, I ; Morgan, M ; Krons, A ; Tchebotarenko, I ; Ihlenburg-Schwarz, D ; Dammann, E ; Collin, M ; Ehrlich, S ; Diedrich, H ; Stadler, M ; Eder, M ; Holler, E ; Mischak, H ; Krauter, J ; Ganser, A 
Abstract
Allogeneic hematopoietic stem cell transplantation is one curative treatment for hematological malignancies, but is compromised by life-threatening complications, such as severe acute graft-versus-host disease (aGvHD). Prediction of severe aGvHD as early as possible is crucial to allow timely initiation of treatment. Here we report on a multicentre validation of an aGvHD-specific urinary ...
Owner only: item control page
Altmetric